ArticleRheumatology (Oxford, England)2020
Remission vs low disease activity: function, quality of life and structural outcomes in the Early Rheumatoid Arthritis Study and Network.
Article in Rheumatology (Oxford, England), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 29 citations in OpenAlex.
- Trial
- Real-world epidemiology and management of patients with rheumatoid arthritis treated with methotrexate in France: a decade after methotrexate first recommendations.EULAR rheumatology open · 2026Article
- Patient-reported outcome measures applied in chronic diseases relevant to asthma remission: a scoping review.European respiratory review : an official journal of the European Respiratory Society · 2026Article
- Traditional clinical risk factors outperform disease activity and hematologic indices for FRAX hip fracture risk in rheumatoid arthritis.Frontiers in immunology · 2026Article
- Add-on iguratimod or tacrolimus in methotrexate in patients with rheumatoid arthritis not achieving remission with methotrexate: a retrospective propensity score-matched study.BMC rheumatology · 2025Article
- Article
- Cost-consequence analysis of tocilizumab versus adalimumab and etanercept among rheumatoid arthritis patients in Saudi Arabia: a single-center study.Cost effectiveness and resource allocation : C/E · 2024Article
- Ten-year radiographic and functional outcomes in rheumatoid arthritis patients in remission compared to patients in low disease activity.Arthritis research & therapy · 2023Article
- Researchers in rheumatology should avoid categorization of continuous predictor variables.BMC medical research methodology · 2023Article
- Comprehensive evaluation of the influence of sex differences on composite disease activity indices for rheumatoid arthritis: results from a nationwide observational cohort study.BMC rheumatology · 2023Article
- Does remission in rheumatoid arthritis bring kinesiophobia, quality of life, fatigue, and physical activity closer to normal?Archives of rheumatology · 2022Article
- Predictors of poor function in RA based on two prospective UK inception cohorts. Do comorbidities matter?Rheumatology (Oxford, England) · 2022Article
- [Innovative strategies for treatment of rheumatoid arthritis].Zeitschrift fur Rheumatologie · 2022Review
- Difficult-to-treat rheumatoid arthritis: Current concept and unsolved problems.Frontiers in medicine · 2022Review
- Clinical conditions needed to acquire sustained functional remission in rheumatoid arthritis patients.Clinical rheumatology · 2021Article
- Are treat-to-target and dose tapering strategies for rheumatoid arthritis possible during the COVID-19 pandemic?The Lancet. Rheumatology · 2020Article
- Use of rheumatoid arthritis impact of disease (RAID) in routine care; identification of DAS28 remission and unmet patient-reported outcomes.Rheumatology advances in practice · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 6 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesTo examine associations between function, quality of life and structural outcomes in patients achieving remission vs low disease activity in early RA.
methodsDemographic, clinical and radiographic variables were collected at baseline and then annually from the Early Rheumatoid Arthritis Study (ERAS) and Early Rheumatoid Arthritis Network (ERAN) inception cohorts in routine care from 1986 to 2012. Disease activity was categorized: mean DAS28 score between years 1 and 5: remission [mean remission DAS (mRDAS) <2.6] or low [mean low DAS (mLDAS) 2.6-3.2]; sustained low/remission DAS28 (sLDAS/sRDAS) at years 1 and 2; and sustained Boolean remission (sBR) at years 1 and 2. Changes in HAQ and Short Form 36 Health Survey Questionnaire [SF-36; physical (PCS) and mental (MCS) component score]) and total Sharp van der Heijde (SvdH) scores for each disease activity category were modelled using multi-level models. Covariates included year of onset, age, gender and DMARD use at first visit.
resultsOf 2701 patients, 562 (21%) were categorized mRDAS, 330 (12%) mLDAS, 279 (10%) sRDAS, 203 (7.5%) sLDAS and 93 (3%) sBR. Patients categorized as mRDAS had increasingly divergent improved HAQ, SF-36 PCS, MCS and total SvdH scores compared with mLDAS (P-values 0.001 to <0.0001, all time points). Patients categorized as sRDAS had better HAQ, SF-36 PCS and MCS scores (P-values 0.05 to <0.0001, all time points) and SvdH scores (P = 0.05, years 3-5) over sLDAS. sBR was associated with better HAQ, and SF-36 PCS and MCS scores over sLDAS (P-values 0.002 to <0.0001, all time points).
conclusionThese findings from routine care support ACR/EULAR guidelines that remission is a preferable goal over low disease activity in early RA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.